[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Meiragtx Holdings Plc (MGTX)

Meiragtx Holdings Plc (MGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,326,354
  • Shares Outstanding, K 96,043
  • Annual Sales, $ 81,390 K
  • Annual Income, $ -114,200 K
  • EBIT $ 184 M
  • EBITDA $ 198 M
  • 60-Month Beta 1.23
  • Price/Sales 16.31
  • Price/Cash Flow N/A
  • Price/Book 5.93

Options Overview Details

View History
  • Implied Volatility 92.76% (-27.02%)
  • Historical Volatility 45.17%
  • IV Percentile 3%
  • IV Rank 4.98%
  • IV High 654.36% on 02/10/26
  • IV Low 63.34% on 06/17/26
  • Expected Move (DTE 17) 0.43 (3.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 231
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,399
  • Open Int (30-Day) 1,365
  • Expected Range 13.77 to 14.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.46
  • Number of Estimates 4
  • High Estimate $-0.37
  • Low Estimate $-0.54
  • Prior Year $-0.62
  • Growth Rate Est. (year over year) +25.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.28 +25.80%
on 08/03/26
15.31 -7.32%
on 08/25/26
+2.40 (+20.36%)
since 07/31/26
3-Month
8.89 +59.62%
on 06/09/26
15.35 -7.56%
on 07/07/26
+4.39 (+44.80%)
since 06/01/26
52-Week
6.62 +114.35%
on 03/05/26
15.35 -7.56%
on 07/07/26
+6.89 (+94.38%)
since 08/29/25

Most Recent Stories

More News
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

NEW YORK , Aug. 26, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company, announced the publication of peer-reviewed data from a multicenter...

MGTX : 14.19 (+2.75%)
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1...

MGTX : 14.19 (+2.75%)
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade...

MGTX : 14.19 (+2.75%)
MeiraGTx Reports Tomorrow: Wall Street Still Pricing In a Company That Exists

Barchart Research What to Expect from MGTX Earnings MGTX Generated August 12, 2026 Current Price $12.96 EPS Estimate $$-0.39 Consensus Rating Strong Buy Average Move 7.17% MeiraGTx Reports Tomorrow: Wall...

MGTX : 14.19 (+2.75%)
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

NEW YORK , Aug. 11, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective...

MGTX : 14.19 (+2.75%)
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee...

MGTX : 14.19 (+2.75%)
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee...

MGTX : 14.19 (+2.75%)
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment Following regulatory approval, Oberland Capital to receive low single-digit capped royalties...

MGTX : 14.19 (+2.75%)
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to...

MGTX : 14.19 (+2.75%)
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines...

MGTX : 14.19 (+2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR,...

See More

Key Turning Points

3rd Resistance Point 15.58
2nd Resistance Point 15.09
1st Resistance Point 14.64
Last Price 14.19
1st Support Level 13.70
2nd Support Level 13.21
3rd Support Level 12.76

See More

52-Week High 15.35
Last Price 14.19
Fibonacci 61.8% 12.02
Fibonacci 50% 10.99
Fibonacci 38.2% 9.95
52-Week Low 6.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.